RSS-Feed abonnieren
DOI: 10.1007/s12593-015-0196-0
Experimental Thromboprophylaxis with Low Molecular Weight Heparin After Microsurgical Revascularization
Verantwortlicher Herausgeber dieser Rubrik:
Publikationsverlauf
21. Januar 2015
30. Juli 2015
Publikationsdatum:
13. September 2016 (online)

Abstract
There is great variability among microsurgeons as regards the use of prophylactic anticoagulant after revascularization and this is probably due to lack of comparative data. Also, there has been much debate regarding the benefit of anti-thrombotic therapies versus the risk of complications such as systemic bleeding and hematoma formation. To evaluate the effectiveness of postoperative low molecular weight heparin (LMWH) as a prophylactic anticoagulant therapy after microsurgical repair of the femoral artery and vein in rats. Randomized, blinded study. The femoral artery and vein of 40 Sprague Dawley rats were sectioned and repaired with microsurgical sutures under general anesthesia. They were randomly divided into 2 groups: Group (A) in which the 20 rats were injected with Enoxaparin subcutaneously at a dose 1.5 mg/kg once daily for 3 successive days; Group (B), the control group, in which 20 rats were injected with isotonic sodium chloride 0.9 % subcutaneously in a blinded fashion. After 7 days, the femoral vessels were re-explored and patency of the femoral vessels was assessed with empty-and-refill test. There were a total of 12 vascular thrombosis among 74 microsurgical repair in both groups with percentage of 16.22 % including, 5 arterial anastomosis and 7 venous anastomosis. The incidence of thrombosis in the treatment group (A) was 18.4 % while the incidence of thrombosis in the control group (B) was 13.8 %. This difference was not statistically significant using Fisher exact test. Postoperative administration of LMWH did not provide the desired protection against thrombosis after microsurgical vascular repair.
-
References
- 1 Iglasias M, Butron P. Local subcutaneous heparin as treatment for venous insufficiency in replanted digits. Plast Reconstr Surg 1999; 103: 1719-1724
- 2 Levin LS, Cooper EO. Clinical use of anticoagulants following replantation surgery. J Hand Surg 2008; 33: 1437-1439
- 3 Li X, Cooley BC. Effect of anticoagulation and inhibition of platelet aggregation on arterial versus venous microvascular thrombosis. Ann Plast Surg 1995; 2: 165-169
- 4 Disa JJ, Cordeiro PG, Hidalgo DA. Efficacy of conventional monitoring techniques in free tissue transfer: an 11-year experience in 750 consecutive cases. Plast Reconstr Surg 1999; 104: 97-101
- 5 Khouri RK, Cooley BC, Kenna DM, Edstrom LE. Thrombosis of microvascular anastomoses in traumatized vessels: fibrin versus platelets. Plast Reconstr Surg 1990; 86: 110-117
- 6 Salzman EW, Deykin D, Shapiro RM, Rosenberg R. Management of heparin therapy: controlled prospective trial. N Engl J Med 1975; 292: 1046-1050
- 7 Nenci GG, Minciotti A. Low molecular weight heparins for arterial thrombosis. Vasc Med 2000; 4: 251-258
- 8 Buckley T, Hammert WC. Anticoagulation following digital replantation. J Hand Surg [Am] 2011; 8: 1374-1376
- 9 Lecoq JP, Senard M, Hartstein GM, Lamy M, Heymans O. Thromboprophylaxis in microsurgery. Acta Chir Belg 2006; 2: 158-164
- 10 Davis DM. A world survey of anticoagulation practice in clinical microvascular surgery. Br J Plast Surg 1982; 35: 96-99
- 11 Johnson PC, Barker JH. Thrombosis and antithrombotic therapy in microvascular surgery. Clin Plast Surg 1992; 19: 799-807
- 12 Das SK, Miller JH. Current status of topical antithrombotic agents in microvascular surgery. Microsurgery 1994; 15: 630-632
- 13 Askari M, Fisher C, Weniger FG, Bidic S, Lee WP. Anticoagulation therapy in microsurgery: a review. J Hand Surg [Am] 2006; 5: 836-846
- 14 Khouri RK, Cooley BC, Kunselman AR et al A prospective study of microvascular free-flap surgery and outcome. Plast Reconstr Surg 1998; 3: 711-721
- 15 Veravuthipakorn L, Veravuthipakorn A. Microsurgical free flap and replantation without antithrombotic agents. J Med Assoc Thail 2004; 87: 665-669
- 16 Bijsterveld NR, Hettiarachchi R, Peters R, Prins MH, Levi M, Buller HR. Low-molecular weight heparin in venous and arterial thrombotic disease. Thromb Haemost 1999; 82: 139-147
- 17 Ritter EF, Cronan JC, Rudner AM, Seraftn D, Klitzman B. Improved microsurgical anastomotic patency with low molecular weight heparin. J Reconstr Microsurg 1998; 14: 331-336
- 18 Malm K, Dahlbäck B, Arnljots B. Low molecular-weight heparin (Dalteprin) effectively prevents thrombosis in a rat model of deep arterial injury. Plast Reconstr Surg 2003; 111: 1659-1666
- 19 Zhang B, Dougan P, Wieslander JB. A comparison of the early antithrombotic effects between low molecular weight heparin in small arteries following a severe trauma: an experimental study. Ann Plast Surg 1993; 31: 255-261
- 20 Hadlock TA, Kim J, Deschler DG. The effect of subcutaneously administered low-molecular-weight heparin on microarterial thrombosis in the rat. Arch Facial Plast Surg 2003; 1: 36-39
- 21 Emerick KS, Deschler DG. The effect of low-molecular-weight heparin on microvenous thrombosis in a rat model. Arch Facial Plast Surg 2007; 1: 19-21